Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Javier Cortes, MD, PhD
Komal Jhaveri, MD, FACP
ATTRv-PN: A Family Affair?
John Berk, MD
Noel Dasgupta, MD, FACC
Shh…Gene-Silencing Therapies for ATTRv-PN
Sami Khella, MD
Marcia Waddington-Cruz, MD, PhD
Advancing the Treatment of ATTRv-PN: What's in the Pipeline?
Raising the Red Flag: What's Your Index of Suspicion for ATTRv-PN?
ATTR Amyloidosis: Familial Vs Wild-Type
Making the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying
Carl Regillo, MD
Jennifer I. Lim, MD, FARVO
Duchenne Muscular Dystrophy: Differentiating Advances in Treatment
Omer Abdul Hamid, MD
Nancy Kuntz, MD
Migvis Monduy, MD
Quality Indicators: How Do You Compare? Part 1
Douglas Rex, MD
Aasma Shaukat, MD, MPH
Quality Indicators: How Do You Compare? Part 2
David Johnson, MD
Screening Colonoscopy in 2024 and Beyond
Don't Flush Another Colonoscopy Down the Toilet
Bowel Prep Hesitancy: What's It All About?
Risk Reduction and Management Protocols for Gastrointestinal Adverse Events With ADC Therapy in Breast Cancer
Nadia Harbeck, MD, PhD
ADCs on the Horizon for Breast Cancer: Managing Treatment-Emergent Toxicities
Managing Pulmonary and Cardiac Adverse Events Related to ADC Therapy in Breast Cancer
Loading...
We’re glad to see you’re enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.